Based in Montreal, Canada, Alethia BioTherapeutics uses its patented STAR discovery technology to develop therapeutics that focus on invasive carcinomas and cancer-associated epithelial-to-mesenchymal transition. Its products include Isogranulatimide, a G2 checkpoint inhibitor that enhances the response to several DNA-damaging chemotherapeutic agents; sCLU, a glycoprotein overexpressed in various malignancies; AB-0447, an antigen expressed in over 85% of ovarian cancer epithelial cells; and AB-0440, a cell-surface protease-like protein stimulated early in osteoclast differentiation in response to RANK ligand.